Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution
PLOS Biology · 2026-03-03 · 24 (3) · e3003701
DOI: 10.1371/journal.pbio.3003701 ↗At a glance
Journal article in PLOS Biology, published online on 2026-03-03. Written by David A Kennedy. Institution: Department of Biology and Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, Pennsylvania, United States of Am…. Major MEDLINE topics: Measles, Antibodies, Monoclonal, Measles virus. 10 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (original language)
Monoclonal antibody therapies are being developed to treat measles in response to its recent resurgence. These therapies risk driving measles virus evolution in ways that might undermine the protection offered by vaccination, outweighing potential benefits.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Biology and Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, Pennsylvania, United States of America.
ORCID profiles: David A Kennedy
Funding
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Cite
APA
Kennedy, D. A. (2026). Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution. PLOS Biology, 24(3), e3003701. https://doi.org/10.1371/journal.pbio.3003701
Vancouver
Kennedy DA. Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution. PLOS Biology. 2026;24(3):e3003701. doi:10.1371/journal.pbio.3003701
BibTeX
@article{Kennedy2026,
author = {Kennedy, David A},
title = {Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution},
journal = {PLOS Biology},
year = {2026},
volume = {24},
number = {3},
pages = {e3003701},
doi = {10.1371/journal.pbio.3003701}
}
EUVIMED